The Breezula 539% headline is doing a lot of heavy lifting right now.
    4/23/2026

    From the encyclopedia
    Clascoterone →

    Topical androgen-receptor blocker, approved as an acne cream

    Minoxidil →

    Vasodilator used on the scalp and, at low doses, as a tablet

    Dutasteride →

    5-alpha reductase inhibitor that blocks both enzyme types, a stronger DHT blocker than finasteride

    At a glance
    In this research discussion post, the primary subjects mentioned are the tone is 😐 neutral with promising results.

    Other terms

    Breezula shows promising results for hair loss, with one trial showing a 539% improvement and another 168%, but lacks combination data with treatments like minoxidil or dutasteride. Its mechanism differs from finasteride, potentially offering fewer side effects by blocking receptors locally at the follicle.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community Can anyone give me a quick 2026 update of the most promising new hair loss drugs to come?

       47 upvotes 2 months ago
      New hair loss treatments like Breezula and a version of Minoxidil for hair regrowth are in advanced trials and may be available in a few years. Clascoterone and other treatments like oral and topical Minoxidil, Finasteride, and Dutasteride are also discussed, with some users experiencing side effects from Finasteride.

      community Breezula / pyrilutamide vs topical fin / dut for added protection on TRT?

       2 upvotes 5 months ago
      A 35-year-old is considering Breezula, Pyrilutamide, or topical finasteride/dutasteride to protect against hair loss while on testosterone replacement therapy (TRT). They currently use finasteride, oral minoxidil, and dutasteride but experienced increased hair shedding with TRT.

      community Pyrludimide (KX-826) or Breezula (clascoterone)

       9 upvotes 6 months ago
      The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

      community DUPA hitting me in my 30s despite fin + min - Looking for options

      in Basic Questions  310 upvotes 1 month ago
      A 32-year-old experiencing diffuse hair loss despite long-term use of finasteride and oral minoxidil is considering additional treatments like topical dutasteride, RU58841, and Breezula. Concerns about Crohn's disease affecting hair loss and past negative experiences with dutasteride impacting libido are also mentioned.

    Related Research

    6 / 6 results

      research Androgenetic Alopecia: An Update of Treatment Options

      110 citations , August 2016 in “Drugs”
      Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

      research Antiandrogens and Androgen Inhibitors

      November 2020 in “Elsevier eBooks”
      This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.